Pharmaceutical News

RSS

Ivermectin cream demonstrates activity against head lice eggs

In a study sponsored by Topaz Pharmaceuticals Inc., a privately held specialty pharmaceutical company, scientists from the University of Massachusetts, Amherst presented data showing that a 0.5% ivermectin (IVM) cream formulation was active against lice eggs from permethrin resistant head lice.

11 Jul 2011

New corticosteroid with cream-like base

Upsher-Smith Laboratories, Inc. announced the launch of Trianex 0.05% (Triamcinolone Acetonide Ointment), a prescription topical corticosteroid offering the feel of a cream with the strength of an ointment.

11 Jul 2011

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

MonoSol Rx, a specialty pharmaceutical company and the developers of the PharmFilm technology platform, in collaboration with APR Applied Pharma Research s.a. of Switzerland, announced today that its FDA-approved anti-emetic Zuplenz (Ondansetron) oral soluble film is available for licensing to new commercial partners.

11 Jul 2011

USANA receives FDA registration to manufacture OTC drugs

USANA Health Sciences, Inc. today announced it has obtained the U.S. Food and Drug Administration's "Drug Establishment Registration," allowing the company to manufacture over-the-counter (OTC) drugs and holding it to a standard well above what is required of a dietary supplement manufacturer.

11 Jul 2011

Nevada District Court rules in favor of PDL over Genentech, Roche lawsuit

PDL BioPharma, Inc. (PDL) announced a favorable ruling today, specifically, that on July 7, 2011, the Second Judicial District Court of Nevada ruled in favor of PDL on two motions to dismiss filed by Genentech and F. Hoffmann LaRoche, Ltd. in PDL's lawsuit related to the 2003 settlement agreement with Genentech.

11 Jul 2011

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Antares Pharma, Inc. today announced an exclusive licensing agreement for Watson to commercialize Antares' topical oxybutynin gel product in the U.S. and Canada.

11 Jul 2011

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

Vanda Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced its exclusive license agreement with Probiomed S.A. de C.V., a wholly owned pharmaceutical operating unit of Proquifin S.A. de C.V., for the commercialization of Fanapt in Mexico.

11 Jul 2011

MSU professor focuses on new formulation for old drug to treat parasitic diseases

With the help of another $2 million in funding from the Bill & Melinda Gates Foundation, researchers are moving closer to setting up human clinical trials for a reformulated drug that could be the linchpin of treatment efforts against two debilitating tropical diseases.

11 Jul 2011

GlaxoSmithKline's Boostrix receives FDA approval to prevent tetanus, diphtheria, and pertussis

The U.S. Food and Drug Administration today approved Boostrix vaccine to prevent tetanus, diphtheria, and pertussis (whooping cough) in people ages 65 and older.

11 Jul 2011

APP receives FDA approval to market Clonidine Hydrochloride Injection

APP Pharmaceuticals, Inc., a wholly owned subsidiary of Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that it has received approval from the U.S. Food and Drug Administration (FDA) to market Clonidine Hydrochloride Injection in two dosage strengths.

11 Jul 2011

FDA approves BOOSTRIX to prevent tetanus, diphtheria and pertussis in older people

The U.S. Food and Drug Administration (FDA) has approved BOOSTRIX for use in adults 65 years of age and older for active booster immunization against tetanus, diphtheria and pertussis.

11 Jul 2011

Flu vaccine against all strains of virus coming soon

A universal flu vaccine, capable of working against all strains, would save lives and money by eliminating the need for the annual jab say experts. Researchers in California and the Netherlands believe they are now a “step closer” to meeting this objective.

10 Jul 2011

Generics as a way to lower health care costs

As the nation seeks to expand health care coverage to more citizens without adding burdensome costs, researchers from Harvard University, Brigham and Women's Hospital and CVS Caremark reported that preventative health care may be significantly less costly than previously thought, due to expanded use of cost-effective generic medications for the treatment and prevention of chronic disease.

8 Jul 2011

Mass administration of common anti-parasitic is possible new tool in fight against malaria

Ivermectin - an inexpensive, common medication already being used in Africa to treat roundworms that cause river blindness and parasites that cause elephantitis - could also be used to kill mosquitoes carrying malaria parasites, potentially "provid[ing] another useful weapon in the armory against a disease that kills around 800,000 a year, most of them small children and pregnant women," the Guardian's "Global Health Blog" reports (Boseley, 7/6).

8 Jul 2011

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Onconova Therapeutics, Inc., and SymBio Pharmaceuticals Limited announced today that they will collaborate to develop and commercialize rigosertib in Japan and Korea. Onconova is conducting late-stage clinical trials with rigosertib (ON 01910.Na) in the U.S., Europe and India for the treatment of Myelodysplastic Syndromes (MDS) and solid tumors.

8 Jul 2011

Shire files lawsuit against Watson over generic Vyvanse

Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market lisdexamfetamine dimesylate capsules. Watson's lisdexamfetamine dimesylate capsules are a generic version of Shire LLC's Vyvanse®.

8 Jul 2011

Study finds higher rate of switching from Byetta to Victoza in treatment of type 2 diabetes

Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that although Amylin/Eli Lilly's Byetta currently commands a higher patient share than Novo Nordisk's Victoza, more patients were switched from Byetta to Victoza than vice versa (25.2 percent versus 2.8 percent) in the last quarter of 2010 among recently treated type 2 diabetes patients.

8 Jul 2011

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

LFB announced today that it has been recently issued U.S. Patent 7,931,895 titled "Monoclonal Antibodies with Enhanced ADCC Function" on April 26, 2011, by the U.S. Patent and Trademark Office.

8 Jul 2011

U.S. District Court rules in favor of Watson over Mucinex patent suit

Watson Pharmaceuticals, Inc. today confirmed that the United States Court of Appeals for the Federal Circuit has affirmed the United States District Court for the Southern District of Florida's February 2011 decision that Watson's generic versions of Mucinex(R), Mucinex(R) D, and Mucinex(R) DM Extended-Release products do not infringe U.S. Patent No. 6,372,252.

8 Jul 2011

Heartworm medication Ivermectin prevents malaria transmission in Africa

A cheap, common heartworm medication that is already being used to fight other parasites in Africa could also dramatically interrupt transmission of malaria, potentially providing an inexpensive tool to fight a disease that kills almost 800,000 people each year, according to a new study published in the July edition of the American Journal of Tropical Medicine and Hygiene.

7 Jul 2011

Pharmaceutical News

Ivermectin cream demonstrates activity against head lice eggs

New corticosteroid with cream-like base

FDA-approved Zuplenz oral soluble film now available for licensing to new commercial partners

USANA receives FDA registration to manufacture OTC drugs

Nevada District Court rules in favor of PDL over Genentech, Roche lawsuit

Antares, Watson enter license deal to commercialize Anturol in the U.S. and Canada

Probiomed, Vanda enter license deal to commercialize Fanapt in Mexico

MSU professor focuses on new formulation for old drug to treat parasitic diseases

GlaxoSmithKline's Boostrix receives FDA approval to prevent tetanus, diphtheria, and pertussis

APP receives FDA approval to market Clonidine Hydrochloride Injection

FDA approves BOOSTRIX to prevent tetanus, diphtheria and pertussis in older people

Flu vaccine against all strains of virus coming soon

Generics as a way to lower health care costs

Mass administration of common anti-parasitic is possible new tool in fight against malaria

Onconova, SymBio enter commercialization collaboration for rigosertib in Japan and Korea

Shire files lawsuit against Watson over generic Vyvanse

Study finds higher rate of switching from Byetta to Victoza in treatment of type 2 diabetes

LFB receives U.S. patent titled 'Monoclonal Antibodies with Enhanced ADCC Function'

U.S. District Court rules in favor of Watson over Mucinex patent suit

Heartworm medication Ivermectin prevents malaria transmission in Africa

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News